The Future in Cannabis. WorldWide.

Tag: Cannabinoids

How is Michigan doing with its new Medical Cannabis Laws?

For those looking to get into this “Green Rush” it is critically important that one understands that this business is not designed to accommodate the novice Medical Cannabis entrepreneur and investor.  

The Michigan Medical Cannabis Industry is being regulated by LARA the Department of Licensing and Regulated Affairs. LARA has created a special unit for the regulation of medical marijuana called the Bureau of Medical Marijuana. The Bureau of Medical Marijuana regulates the Michigan’s medical marihuana facilities and licensees, including growers, processors, transporters, provisioning centers and safety compliance facilities.  The bureau also oversees the Michigan’s patient registry program and administers the Michigan Medical Marihuana Act.

For those looking to develop a career and invest into Michigan’s Medical Cannabis Industry it is important that you are aware that the new Michigan Medial Cannabis laws have designate five classes of licenses that will be available for qualified Michigan applicants:

  1. A growers license with three classes of growers
    • Class A – people who can grow up to 500 plants,
    • Class B – people who can grow up to 1,000 plants,
    • Class C – or up to 1,500 plants.
  2. A processor license
  3. A safety compliance facility license (Lab)
  4. A secure transporter license
  5. A provisioning center license (Dispensary)

Back in January 16, 2017 a well written article “New laws in Michigan shake up the marijuana industry” by Christian Sheckler South Bend Tribune sharing with Michigan’s Medical Cannabis Patient, Caregiver, and General Public that BIG changes are coming.  These changes are important as Michigan’s registered Medical Cannabis Patients are above 2oo,ooo and climbing.  This large number of register patients drives the logic behind rolling out this Medical Cannabis Industry in a cogent and regulated way.  

In theory, depending of course on many other factors that can be considered as basic “business 101” knowledge, the current Michigan Cannabis Caregiver should have some advantages in dealing with LARA’s medical marijuana regulations.  Provided  with the proper council and advise, assuming they follow the complex and ever changing laws, this new legislation could transform the former Caregivers learned skill set into a BIG Business. If you are qualified and acquire any of the 3 proposed classes of growers licenses this could be a once in a lifetime opportunity.  It does indeed appear the grass is greener on the other side!

National Academies of Science, Engineering and Medicine Cannabis Study

 On January 12th, the National Academies of Science, Engineering and Medicine (NASEM) released a study detailing their recommendations on the use of cannabis and cannabinoids. The study was based on a comprehensive examination of more than 10,000 research abstracts published after 1999 covering the effects of cannabis on 11 categories of health topics and concerns, including therapeutic; cancer incidence; respiratory disease; prenatal, perinatal, and neonatal outcomes; psychosocial and mental health concerns. The full study can be found here (link).

One of the major concerns from the research committee was that there are specific regulatory barriers, including the classification of cannabis as a Schedule I substance, that impede the advancement of cannabis and cannabinoid research. However, the study did detail several positive results on the impact of cannabis and cannabinoids for therapeutic usage including;

  1. Conclusive evidence of the effectiveness of treatment for chronic pain in adults, antiemetic’s in the treatment of chemotherapy-induced nausea and vomiting (oral cannabinoids) and for improving patient-reported multiple sclerosis spasticity symptoms (oral cannabinoids).
  2. Moderate evidence of the effectiveness of improving short-term sleep outcomes in individuals with sleep disturbance associated with obstructive sleep apnea syndrome, fibromyalgia, chronic pain, and multiple sclerosis (cannabinoids, primarily nabiximols (Trade name Sativex)).
  3. Limited evidence of the effectiveness of increasing appetite and decreasing weight loss associated with HIV/AIDS (cannabis and oral cannabinoids), improving clinician-measured multiple sclerosis spasticity symptoms (oral cannabinoids), improving symptoms of Tourette syndrome (THC capsules), improving anxiety symptoms, as assessed by a public speaking test, in individuals with social anxiety disorders (cannabidiol) and improving symptoms of posttraumatic stress disorder.

The committee had determined that “conclusive” in this case represented evidence with many supportive findings from good-quality studies with no credible opposing findings. “Moderate” evidence being findings from good- to fair-quality studies with very few or no credible opposing findings and “limited” relating to supportive findings from fair-quality studies or mixed findings with most favouring one conclusion. Even with the Committee’s concerns on the regulatory barriers limiting proper access and information, these findings represent a major step forward for an industry still searching for wide spread legitimacy.

The NASEM committee added a number of recommendations on the advancement of research and understanding the long-term effects of cannabis including;

  1. To develop a comprehensive evidence data base on the short- and long-term health effects of cannabis use (both beneficial and harmful effects) that addresses key gaps in the current evidence.
  2. To promote the development of conclusive evidence on the short- and long-term health effects of cannabis use.
  3. To ensure that sufficient data is available to inform research on the short- and long-term health effects of cannabis use.
  4. The development of a committee of experts tasked to produce an objective and evidence-based report that fully characterizes the impacts of regulatory barriers to cannabis research and that proposes strategies for supporting development of the resources and infrastructure necessary to conduct a comprehensive cannabis research agenda.

Basically the committee has concluded that there is conclusive evidence to show the use of cannabis and cannabinoids has tremendous therapeutic results but the total impact and long terms results are not yet known due to a lack data, insufficient research and regulatory barriers.

Medical Marijuana – A CFL Boon?

football_cannabis_300On the day of Super Bowl 50, we look at the role of medical marijuana in professional sports. Former Toronto Argonaut, Ricky Williams believes that MMJ is crucial to saving all of football. He credits marijuana for preserving his health during his football career and other players say that cannabis helps them avoid painkiller addiction.

According to this article, currently CFL players who want to use marijuana for pain management can do so, providing there are no legal issues obtaining it or using it. By contrast, the NFL is still trying to prohibit its use despite an estimated 60% of NFL players smoke marijuana and an estimated 70 – 90% of players who use prescription painkillers during their playing career went on to abuse them.

The CFL’s lack of testing for cannabis means that players are already exploring it as an alternative to prescription painkillers. As pressure increases to ensure player safety in the NFL, the league should take a few notes from Canada’s playbook to allow medical marijuana as an alternative to prescription drugs for pain management.

TheraCann Partners with Bokashicycle

bokashicycle_fermentorJanuary 5, 2015: Bokashicycle, of Lakewood Washington, today announced a new Distributor Agreement with TheraCann International Corporation (formerly Benchmark Labs) to provide their easy to implement and complete fermentation system as part of the TheraCann comprehensive, and truly “Turn-Key” infrastructure solution to medical marijuana producers through North America. Under the agreement, TheraCann will provide, install and maintain Bokashicycle technology to TheraCann Labs clients.

“We are looking forward to working with you and your [TheraCann] Team assisting and improving on ways in which marijuana growers process their waste materials” said Dr. Larry Green, President of Bokashicycle.

Read more